TRACON Pharmaceuticals Ownership 2024 | Who Owns TRACON Pharmaceuticals Now?


OverviewRevenueFinancialsChartTranscripts

Institutional Ownership

9.35%

Insider Ownership

2.20%

Retail Ownership

88.44%

Institutional Holders

27.00

TRACON Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LPL FINANCIAL LLC1.38%0.00%450,650450,650100.00%193,689Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC1.26%0.00%413,909--176,000Mar 31, 2024
SQUAREPOINT OPS LLC1.19%0.00%388,985-23,286-5.65%167,186Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.92%0.00%300,238202,200206.25%129,000Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.88%-286,70977,92337.32%123,228Mar 31, 2024
VANGUARD GROUP INC0.80%-262,772--112,939Mar 31, 2024
BLACKROCK INC.0.79%-260,084-1,178-0.45%111,784Mar 31, 2024
JANE STREET GROUP, LLC0.56%-182,307182,307100.00%78,356Mar 31, 2024
UBS GROUP AG0.28%-91,33391,333100.00%39,273Mar 31, 2024
JOHNSON & JOHNSON0.26%0.00%84,003--36,104Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.24%-77,86877,868100.00%33,468Mar 31, 2024
STATE STREET CORP0.23%-75,154--32,301Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.23%-74,658-116,795-61.00%32,088Mar 31, 2024
CI PRIVATE WEALTH, LLC0.18%-57,455--24,695Mar 31, 2024
HRT FINANCIAL LP0.17%0.00%54,36454,364100.00%23,000Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.11%-34,82234,822100.00%14,966Mar 31, 2024
XTX TOPCO LTD0.09%0.00%27,96527,965100.00%12,019Mar 31, 2024
ETF PORTFOLIO PARTNERS, INC.0.08%0.00%24,64124,641100.00%10,591Mar 31, 2024
SPIDERROCK ADVISORS, LLC0.07%0.00%22,98322,983100.00%8,299Mar 31, 2024
NORTHERN TRUST CORP0.07%-21,691--9,323Mar 31, 2024

TRACON Pharmaceuticals's largest institutional shareholder is LPL FINANCIAL LLC, holding 1.38% of the company's total share outstanding, currently valued at $193.69K. The top 10 institutional shareholders own together 8.31% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ETF PORTFOLIO PARTNERS, INC.0.08%0.00%24,64124,641100.00%10,591Mar 31, 2024
XTX TOPCO LTD0.09%0.00%27,96527,965100.00%12,019Mar 31, 2024
JOHNSON & JOHNSON0.26%0.00%84,003--36,104Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC1.26%0.00%413,909--176,000Mar 31, 2024
HOYLECOHEN, LLC0.04%0.00%13,000--5,588Mar 31, 2024
SQUAREPOINT OPS LLC1.19%0.00%388,985-23,286-5.65%167,186Mar 31, 2024
GAME PLAN FINANCIAL ADVISORS, LLC0.00%0.00%1,000--430Mar 31, 2024
SPIDERROCK ADVISORS, LLC0.07%0.00%22,98322,983100.00%8,299Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.92%0.00%300,238202,200206.25%129,000Mar 31, 2024
HRT FINANCIAL LP0.17%0.00%54,36454,364100.00%23,000Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%10,50010,500100.00%4,515Mar 31, 2024
LPL FINANCIAL LLC1.38%0.00%450,650450,650100.00%193,689Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%7,579-2,786-26.88%3,259Mar 31, 2024
TRUVESTMENTS CAPITAL LLC0.00%0.00%318--137,000Mar 31, 2024
CI PRIVATE WEALTH, LLC0.18%-57,455--24,695Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.11%-34,82234,822100.00%14,966Mar 31, 2024
JANE STREET GROUP, LLC0.56%-182,307182,307100.00%78,356Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.23%-74,658-116,795-61.00%32,088Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.88%-286,70977,92337.32%123,228Mar 31, 2024
MERCER GLOBAL ADVISORS INC /ADV0.03%-10,00010,000100.00%4,000Mar 31, 2024

The largest TRACON Pharmaceuticals shareholder by % of total assets is ETF PORTFOLIO PARTNERS, INC.. The company owns 24.64K shares of TRACON Pharmaceuticals (TCON), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LPL FINANCIAL LLC1.38%0.00%450,650450,650100.00%193,689Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.92%0.00%300,238202,200206.25%129,000Mar 31, 2024
JANE STREET GROUP, LLC0.56%-182,307182,307100.00%78,356Mar 31, 2024
UBS GROUP AG0.28%-91,33391,333100.00%39,273Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.88%-286,70977,92337.32%123,228Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.24%-77,86877,868100.00%33,468Mar 31, 2024
HRT FINANCIAL LP0.17%0.00%54,36454,364100.00%23,000Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.11%-34,82234,822100.00%14,966Mar 31, 2024
XTX TOPCO LTD0.09%0.00%27,96527,965100.00%12,019Mar 31, 2024
ETF PORTFOLIO PARTNERS, INC.0.08%0.00%24,64124,641100.00%10,591Mar 31, 2024
SPIDERROCK ADVISORS, LLC0.07%0.00%22,98322,983100.00%8,299Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%10,50010,500100.00%4,515Mar 31, 2024
MERCER GLOBAL ADVISORS INC /ADV0.03%-10,00010,000100.00%4,000Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-20731.47%89,000Mar 31, 2024
BANK OF NEW YORK MELLON CORP0.03%-10,259--4,409Mar 31, 2024
STATE STREET CORP0.23%-75,154--32,301Mar 31, 2024
NORTHERN TRUST CORP0.07%-21,691--9,323Mar 31, 2024
VANGUARD GROUP INC0.80%-262,772--112,939Mar 31, 2024
CI PRIVATE WEALTH, LLC0.18%-57,455--24,695Mar 31, 2024
TRUVESTMENTS CAPITAL LLC0.00%0.00%318--137,000Mar 31, 2024

As of Mar 31 2024, TRACON Pharmaceuticals's largest institutional buyer is LPL FINANCIAL LLC. The company purchased 450.65K stocks of TCON, valued at $193.69K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
IKARIAN CAPITAL, LLC----2,765,530-100.00%-Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC----258,844-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.23%-74,658-116,795-61.00%32,088Mar 31, 2024
SQUAREPOINT OPS LLC1.19%0.00%388,985-23,286-5.65%167,186Mar 31, 2024
GTS SECURITIES LLC----15,794-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%7,579-2,786-26.88%3,259Mar 31, 2024
BLACKROCK INC.0.79%-260,084-1,178-0.45%111,784Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD----800-100.00%-Mar 31, 2024
MORGAN STANLEY----201-100.00%-Mar 31, 2024
JOHNSON & JOHNSON0.26%0.00%84,003--36,104Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC1.26%0.00%413,909--176,000Mar 31, 2024
HOYLECOHEN, LLC0.04%0.00%13,000--5,588Mar 31, 2024
GAME PLAN FINANCIAL ADVISORS, LLC0.00%0.00%1,000--430Mar 31, 2024
TRUVESTMENTS CAPITAL LLC0.00%0.00%318--137,000Mar 31, 2024
CI PRIVATE WEALTH, LLC0.18%-57,455--24,695Mar 31, 2024
VANGUARD GROUP INC0.80%-262,772--112,939Mar 31, 2024
NORTHERN TRUST CORP0.07%-21,691--9,323Mar 31, 2024
STATE STREET CORP0.23%-75,154--32,301Mar 31, 2024
BANK OF NEW YORK MELLON CORP0.03%-10,259--4,409Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-20731.47%89,000Mar 31, 2024

As of Mar 31 2024, TRACON Pharmaceuticals's biggest institutional seller is IKARIAN CAPITAL, LLC. The company sold -2.77M shares of TCON, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LPL FINANCIAL LLC1.38%0.00%450,650450,650100.00%193,689Mar 31, 2024
JANE STREET GROUP, LLC0.56%-182,307182,307100.00%78,356Mar 31, 2024
UBS GROUP AG0.28%-91,33391,333100.00%39,273Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.24%-77,86877,868100.00%33,468Mar 31, 2024
HRT FINANCIAL LP0.17%0.00%54,36454,364100.00%23,000Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.11%-34,82234,822100.00%14,966Mar 31, 2024
XTX TOPCO LTD0.09%0.00%27,96527,965100.00%12,019Mar 31, 2024
ETF PORTFOLIO PARTNERS, INC.0.08%0.00%24,64124,641100.00%10,591Mar 31, 2024
SPIDERROCK ADVISORS, LLC0.07%0.00%22,98322,983100.00%8,299Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%10,50010,500100.00%4,515Mar 31, 2024
MERCER GLOBAL ADVISORS INC /ADV0.03%-10,00010,000100.00%4,000Mar 31, 2024

TRACON Pharmaceuticals's largest new institutional shareholder by number of shares is LPL FINANCIAL LLC, purchased 450.65K shares, valued at $193.69K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
IKARIAN CAPITAL, LLC----2,765,530-100.00%-Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC----258,844-100.00%-Mar 31, 2024
GTS SECURITIES LLC----15,794-100.00%-Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD----800-100.00%-Mar 31, 2024
MORGAN STANLEY----201-100.00%-Mar 31, 2024

TRACON Pharmaceuticals's largest sold out institutional shareholder by shares sold is IKARIAN CAPITAL, LLC, sold -2.77M shares, valued at -, as of undefined.

TRACON Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.03%13,800--Dec 31, 2023
BRIDGEWAY FUNDS INC0.02%60,000--Dec 29, 2023
BRIDGEWAY FUNDS INC0.00%6,000--Dec 29, 2023
VANGUARD INDEX FUNDS0.00%525,544-98,854-15.83%Dec 31, 2023
T. Rowe Price Index Trust, Inc.0.00%17,400--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%200,699--Feb 29, 2024
AdvisorShares Trust0.00%1,772--Dec 29, 2023
SCHWAB CAPITAL TRUST0.00%22,638--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%11,168--Dec 31, 2023
Legg Mason Global Asset Management Trust0.00%42,900--Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%5,100--Jan 31, 2024
SUNAMERICA SERIES TRUST0.00%800--Jan 31, 2024
EQ ADVISORS TRUST0.00%2,599--Dec 31, 2023

TRACON Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 13.80K shares, compromising 0.03% of its total assets.

TRACON Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 242722.73%
31 Dec, 232222.22%
30 Sep, 2318-28.00%
30 Jun, 2325-21.88%
31 Mar, 2332-5.88%
31 Dec, 22346.25%
30 Sep, 22323.23%
30 Jun, 2231-18.42%
31 Mar, 22382.70%
31 Dec, 2137-17.78%
30 Sep, 21452.27%
30 Jun, 21447.32%
31 Mar, 21412.50%
31 Dec, 204060.00%
30 Sep, 202538.89%
30 Jun, 2018-
31 Mar, 201838.46%
31 Dec, 1913-

As of 31 Mar 24, 27 institutions are holding TRACON Pharmaceuticals's shares, representing an increase of 22.73% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 243,063,147-40.67%
31 Dec, 235,163,109-44.46%
30 Sep, 239,296,999-6.66%
30 Jun, 239,959,9330.53%
31 Mar, 239,907,7870.86%
31 Dec, 229,823,276-0.27%
30 Sep, 229,849,440-0.22%
30 Jun, 229,871,3398.10%
31 Mar, 229,131,314-0.10%
31 Dec, 219,140,084-10.67%
30 Sep, 2110,231,47613.88%
30 Jun, 218,984,779-1.78%
31 Mar, 219,147,2498.22%
31 Dec, 208,452,46147.67%
30 Sep, 205,723,970268.36%
30 Jun, 201,553,91722.72%
31 Mar, 201,266,24162.85%
31 Dec, 19777,529-

TRACON Pharmaceuticals (TCON) has 3.06M shares outstanding as of 31 Mar 24, down -40.67% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 249.35%4.74%
31 Dec, 2314.04%1.54%
30 Sep, 2330.21%1.71%
30 Jun, 2342.02%2.40%
31 Mar, 2341.80%1.90%
31 Dec, 2246.96%2.23%
30 Sep, 2245.88%1.93%
30 Jun, 2248.70%2.25%
31 Mar, 2246.57%1.66%
31 Dec, 2152.98%1.74%
30 Sep, 2155.20%1.64%
30 Jun, 2157.98%1.66%
31 Mar, 2159.09%1.98%
31 Dec, 2054.60%1.84%
30 Sep, 2054.47%9.20%
30 Jun, 2024.33%4.06%
31 Mar, 2024.49%4.04%
31 Dec, 1924.61%-

As of 31 Mar 24, TRACON Pharmaceuticals is held by 9.35% institutional shareholders, representing a 4.74% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 241362.50%
31 Dec, 238100.00%
30 Sep, 234-33.33%
30 Jun, 236-33.33%
31 Mar, 239-25.00%
31 Dec, 2212140.00%
30 Sep, 225-44.44%
30 Jun, 229-40.00%
31 Mar, 221536.36%
31 Dec, 2111-45.00%
30 Sep, 212053.85%
30 Jun, 2113-43.48%
31 Mar, 2123-14.81%
31 Dec, 202780.00%
30 Sep, 201536.36%
30 Jun, 2011-
31 Mar, 2011-15.38%
31 Dec, 1913-

13 institutional shareholders have increased their position in TCON stock as of 31 Mar 24 compared to 8 in the previous quarter (a 62.50% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 244-20.00%
31 Dec, 23566.67%
30 Sep, 233-25.00%
30 Jun, 234-20.00%
31 Mar, 235-28.57%
31 Dec, 227-12.50%
30 Sep, 228-
30 Jun, 228-
31 Mar, 228-
31 Dec, 218-11.11%
30 Sep, 219-30.77%
30 Jun, 211362.50%
31 Mar, 218100.00%
31 Dec, 204-
30 Sep, 204300.00%
30 Jun, 201-66.67%
31 Mar, 203-
31 Dec, 19--

4 institutional shareholders have reduced their position in TCON stock as of 31 Mar 24 compared to 5 in the previous quarter (a -20.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 242722.73%3,063,147-40.67%9.35%4.74%1362.50%4-20.00%
31 Dec, 232222.22%5,163,109-44.46%14.04%1.54%8100.00%566.67%
30 Sep, 2318-28.00%9,296,999-6.66%30.21%1.71%4-33.33%3-25.00%
30 Jun, 2325-21.88%9,959,9330.53%42.02%2.40%6-33.33%4-20.00%
31 Mar, 2332-5.88%9,907,7870.86%41.80%1.90%9-25.00%5-28.57%
31 Dec, 22346.25%9,823,276-0.27%46.96%2.23%12140.00%7-12.50%
30 Sep, 22323.23%9,849,440-0.22%45.88%1.93%5-44.44%8-
30 Jun, 2231-18.42%9,871,3398.10%48.70%2.25%9-40.00%8-
31 Mar, 22382.70%9,131,314-0.10%46.57%1.66%1536.36%8-
31 Dec, 2137-17.78%9,140,084-10.67%52.98%1.74%11-45.00%8-11.11%
30 Sep, 21452.27%10,231,47613.88%55.20%1.64%2053.85%9-30.77%
30 Jun, 21447.32%8,984,779-1.78%57.98%1.66%13-43.48%1362.50%
31 Mar, 21412.50%9,147,2498.22%59.09%1.98%23-14.81%8100.00%
31 Dec, 204060.00%8,452,46147.67%54.60%1.84%2780.00%4-
30 Sep, 202538.89%5,723,970268.36%54.47%9.20%1536.36%4300.00%
30 Jun, 2018-1,553,91722.72%24.33%4.06%11-1-66.67%
31 Mar, 201838.46%1,266,24162.85%24.49%4.04%11-15.38%3-
31 Dec, 1913-777,529-24.61%-13---

TRACON Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy47,000$0.75$35.25K399,417
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy3,999$0.66$2.64K352,417
Mar 13, 2023Opaleye Management Inc.10 percent owner-P-PurchaseBuy174,508$1.38$240.82K4,324,508
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy4,800$1.52$7.30K344,918
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy200$1.52$304.00340,118

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy47,000$0.75$35.25K399,417
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy3,999$0.66$2.64K352,417
Mar 13, 2023Opaleye Management Inc.10 percent owner-P-PurchaseBuy174,508$1.38$240.82K4,324,508
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy4,800$1.52$7.30K344,918
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy200$1.52$304.00340,118

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 09, 2023Adams Bonne J.officer Chief Operating OfficerSell---4,267

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 13, 2024Lazar David E.-Buy----
Mar 13, 2024Brown Scott B.officer CHIEF FINANCIAL OFFICERA-AwardBuy224,800$0.39$87.67K224,800
Mar 13, 2024Brown Scott B.officer CHIEF FINANCIAL OFFICERA-AwardBuy3,500$0.14$481.9525,128
Mar 13, 2024THEUER CHARLESdirector, officer PRESIDENT AND CEOA-AwardBuy518,300$0.39$202.14K518,300
Mar 13, 2024THEUER CHARLESdirector, officer PRESIDENT AND CEOA-AwardBuy3,500$0.13$466.55406,417
Mar 13, 2024THEUER CHARLESdirector, officer PRESIDENT AND CEOA-AwardBuy3,500$0.14$481.95402,917
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy47,000$0.75$35.25K399,417
Apr 28, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy3,999$0.66$2.64K352,417
Apr 21, 2023Johnson-Pratt Lisadirector-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023Lam Carol C.director-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023PELLETIER SAUNDRA Ldirector-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023MATTINGLY MARTIN Adirector-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023WORLAND STEPHEN Tdirector-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023LARUE WILLIAM Rdirector-A-AwardBuy18,000$1.82$32.76K18,000
Apr 21, 2023Twiford J Rainerdirector-A-AwardBuy18,000$1.82$32.76K18,000
Mar 13, 2023Opaleye Management Inc.10 percent owner-P-PurchaseBuy174,508$1.38$240.82K4,324,508
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy4,800$1.52$7.30K344,918
Mar 02, 2023THEUER CHARLESdirector, officer President and CEOP-PurchaseBuy200$1.52$304.00340,118
Feb 09, 2023Adams Bonne J.officer Chief Operating OfficerA-AwardBuy99,000$1.70$168.30K99,000
Feb 09, 2023Adams Bonne J.officer Chief Operating OfficerSell---4,267

The last insider sell of TRACON Pharmaceuticals's stock was made by Adams Bonne J. on Feb 09 2023, selling - shares at - per share (valued at -). The last insider buy of TCON was made by THEUER CHARLES on Apr 28 2023, buying 47,000 shares at $0.75 per share (worth $35.25K).

TRACON Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20242--
Q4 20231--
Q2 202311--
Q1 202371070.00%
Q4 2022123400.00%
Q3 202213--
Q2 202235--
Q1 202215--
Q4 202125--
Q3 20214--
Q2 20216--
Q1 20216--
Q4 202011--
Q3 202039--
Q2 202011--
Q1 2020112550.00%
Q4 2019-2-
Q3 20191520.00%
Q2 20195--
Q1 2019-1-

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TRACON Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q4 2023---
Q2 20232--
Q1 20234--
Q4 2022112550.00%
Q3 202213--
Q2 202224--
Q1 202212--
Q4 202124--
Q3 20214--
Q2 2021---
Q1 20212--
Q4 202011--
Q3 202039--
Q2 20205--
Q1 20207--
Q4 2019-2-
Q3 20191--
Q2 2019---
Q1 2019---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of TRACON Pharmaceuticals's stocks.

TRACON Pharmaceuticals Peer Ownership


TickerCompany
ANTXAN2 Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
RZLTRezolute, Inc.
PMVPPMV Pharmaceuticals, Inc.
SIOXSio Gene Therapies Inc.
TPSTTempest Therapeutics, Inc.
HSTOHistogen Inc.
ENOBRenovaro Biosciences Inc.
XOMAXOMA Corporation
IKTInhibikase Therapeutics, Inc.
ACXPAcurx Pharmaceuticals, Inc.
VINCVincerx Pharma, Inc.
CADLCandel Therapeutics, Inc.
BTTXBetter Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
CYCNCyclerion Therapeutics, Inc.
ACHLAchilles Therapeutics plc
ENTXEntera Bio Ltd.
ADXNAddex Therapeutics Ltd
KRONKronos Bio, Inc.

TCON Ownership FAQ


TRACON Pharmaceuticals is owned by institutional shareholders (9.35%), insiders (2.20%), and public (88.44%). The largest institutional shareholder of TRACON Pharmaceuticals is LPL FINANCIAL LLC (1.38% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).

TRACON Pharmaceuticals's major institutional shareholders are LPL FINANCIAL LLC, ACADIAN ASSET MANAGEMENT LLC, SQUAREPOINT OPS LLC, RENAISSANCE TECHNOLOGIES LLC, and GEODE CAPITAL MANAGEMENT, LLC. The top five shareholders own together 5.62% of the company's share outstanding.

As of Mar 2024, there are 27 institutional shareholders of TRACON Pharmaceuticals.

LPL FINANCIAL LLC owns 450.65K shares of TRACON Pharmaceuticals, representing 1.38% of the company's total shares outstanding, valued at $193.69K (as of Mar 2024).

As of Mar 2024, ACADIAN ASSET MANAGEMENT LLC holds 413.91K shares of TRACON Pharmaceuticals (TCON), compromising 1.26% of the company, valued at $176K.

SQUAREPOINT OPS LLC is the third largest holder of TRACON Pharmaceuticals. The company owns 388.98K of the company's shares outstanding (worth $167.19K).